The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

ludc webb

Isabel Goncalves

Professor

ludc webb

Galectin 3 is a powerful risk predictor for recurrent coronary events in acute coronary syndrome patients

Author

  • A. Schiopu
  • T. Yndigegn
  • Anna Helena Maria Grufman
  • J. Nilsson
  • I. Goncalves

Summary, in English

Background: Galectin 3 and ST2 are mediators and biomarkers of myocardial fibrosis and remodeling that have recently entered the clinical practice guidelines as prognostic factors in heart failure patients. Elevated galectin 3 and ST2 levels in acute myocardial infarction patients have also been associated with increased incidence of adverse events during follow-up. Purpose: We aimed to assess the comparative ability of Galectin 3 and ST2 to offer additional prognostic information for risk stratification in acute coronary syndrome (ACS) patients, on top of traditional cardiovascular risk factors and other established prognostic biomarkers. Methods: We measured the levels of galectin 3, ST2, N-terminal pro-B type natriuretic peptide (NTproBNP), high-sensitivity C-reactive protein (hsCRP), highsensitivity troponin T (TnT), cystatin C, and lipids in plasma collected from 524 ACS patients (STEMI, non-STEMI and unstable angina) on day 1 following the acute event. Biomarker levels were correlated with the risk to develop recurrent coronary events, in linear regression models adjusted for age, sex and traditional risk factors (smoking, diabetes mellitus, hypertension, LDL, HDL and triglycerides). Results: During a mean follow-up period of 2.13 years, 63 (12%) of the patients suffered a new coronary event. Baseline galectin 3, ST2, hsCRP, NTproBNP and cystatin C were significantly higher in these patients compared to the event-free controls. In a Cox proportional hazards model with forward step selection that included all biomarkers alongside traditional risk factors, age (HR per year of age 1.06, 95% CI 1.03-1.09), galectin 3 (HR per SD log increase 1.88, 95% CI 1.41- 2.51) and cystatin C (HR per SD log increase 1.39, 95% CI 1.12-1.74) were selected as the only independent predictors of recurrent events in the population. In receiver operating curve (ROC) analyses, addition of galectin 3 significantly improved the c-statistic of the model based on traditional risk factors alone (0.81 vs. 0.76, P

Department/s

  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiology
  • Department of Clinical Sciences, Lund
  • Cardiovascular Research - Translational Studies

Publishing year

2015-08-01

Language

English

Pages

11-11

Publication/Series

European Heart Journal

Volume

36

Issue

Suppl 1

Document type

Conference paper: abstract

Publisher

Oxford University Press

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • galectin 3
  • biological marker
  • cystatin C
  • triacylglycerol
  • amino terminal pro brain natriuretic peptide
  • troponin T
  • C reactive protein
  • lipid
  • high density lipoprotein
  • low density lipoprotein
  • risk
  • acute coronary syndrome
  • patient
  • human
  • European
  • society
  • cardiology
  • model
  • risk factor
  • follow up
  • cardiovascular risk
  • practice guideline
  • hypertension
  • diabetes mellitus
  • event free survival
  • smoking
  • linear regression analysis
  • stratification
  • heart muscle fibrosis
  • unstable angina pectoris
  • non ST segment elevation myocardial infarction
  • acute heart infarction
  • plasma
  • heart failure
  • population
  • proportional hazards model
  • prediction
  • ST segment elevation myocardial infarction

Conference name

ESC Congress 2015

Conference date

2015-08-29 - 2015-09-02

Conference place

London, United Kingdom

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Translational Studies

ISBN/ISSN/Other

  • ISSN: 1522-9645